ENERGIZE
12 Dec 2022
ENERGIZE
NCT03661320
A Study to Compare Chemotherapy Alone Versus Chemotherapy Plus Nivolumab or Nivolumab and BMS-986205, Followed by Continued Therapy After Surgery With Nivolumab or Nivolumab and BMS-986205 in Participants With Muscle Invasive Bladder Cancer
Bristol-Myers Squibb
Cancer Type | Bladder |
---|---|
Trial Type | Treatment |
Phase | Phase III |
Age Range | 18 years and older |
Sex | All |
Tumour Stream | - |
Cancer Stage | Locally Recurrent or Locally Advanced |
Anticipated Start Date | 2018-11-06 |
Anticipated End Date | 2024-01-15 |
Hospital | Calvary North Adelaide Hospital |
---|---|
Clinical Trial Coordinator | Julie Rowe |
julie.rowe@calvarycare.org.au | |
Phone | 08 8239 9536 |
Principal Investigator | Dr Rohit Joshi |
Recruitment Status | Recruiting |
Keep up to date with the latest news and breakthroughs